CHICAGO / Sep 12, 2024 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the beta launch of a patient-facing app, olivia, an AI-enabled personal health concierge to empower individuals to holistically organize, manage, and proactively take control of their own health data. olivia, which is currently only available to beta users, leverages generative AI to provide patients and their caregivers personal, concierge-style support in managing their health. The app has a suite of features that aggregate and structure an individual's personal health information in one cohesive place, help a user track symptoms, prepare for doctors’ appointments, and more.

The current healthcare system often puts the onus on patients to manage their own healthcare data, which is overly burdensome for those who suffer from chronic conditions. Many patients work with providers across systems and specialties, which may create a barrier to accessing a holistic health profile. olivia aims to equip every individual with the tools and information they need to receive the best possible treatment amidst increasing complexity of clinical care.

olivia’s suite of features include:

• Seamless Connection with Providers: Aggregate health records by connecting directly with healthcare providers from various institutions to upload, organize, and manage health records in one convenient place (this includes clinical data, scans, slides, molecular tests, and more)
• Comprehensive Patient Profile: Create a singular profile that aggregates and structures health data, and allows for the downloading and sharing with clinicians
• Appointment Preparation: Prepare for appointments by compiling relevant health data, documents, and key questions that can help guide productive conversations with providers
• Health Monitoring: Track symptoms, sleep, and diet, highlight key trends, and create a health journal

On top of these features, olivia uses the emerging capabilities of generative AI to provide individuals access to a comprehensive view of their health record and personalized insights simply by asking a question to olivia, leveraging its built-in generative AI-enabled assistant that provides individuals support and access to insights in a personalized and secure manner.

"Serving patients is at the core of our mission, and olivia brings that to life in a way that directly benefits patients by helping them aggregate their healthcare data in one place, so they can leverage it to receive the best care possible,” said Eric Lefkofsky, Founder and CEO of Tempus. “olivia leverages the enormous investments we have made on behalf of physicians to help patients aggregate multimodal healthcare data at scale and use AI to derive real time insights. As AI becomes more pervasive, individuals are going to need tools like olivia to ensure they are getting the very best care for themselves and their loved ones.”

For more commentary on olivia from Tempus Founder and CEO, Eric Lefkofsky, visit https://www.tempus.com/resources/content/blog/meet-olivia/.

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the potential impact and indicated use of olivia and the timing of the availability of the tool. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 filed with the Securities and Exchange Commission (“SEC”) as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.